ENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer

Simple item page
dc.contributor.authorMarth, C.
dc.contributor.authorVulsteke, C.
dc.contributor.authorRubio, M. J.
dc.contributor.authorMakker, V.
dc.contributor.authorBraicu, E. I.
dc.contributor.authorMcNeish, I. A.
dc.contributor.authorRadoslaw, M.
dc.contributor.authorAyhan, A.
dc.contributor.authorHasegawa, K.
dc.contributor.authorWu, X.
dc.contributor.authorDutta, L.
dc.contributor.authorXu, C.
dc.contributor.authorKeefe, S. M.
dc.contributor.authorLee, J.
dc.contributor.authorPıgnata, S.
dc.date.accessioned2020-10-20T07:50:22Z
dc.date.available2020-10-20T07:50:22Z
dc.date.issued2019
dc.description.sponsorshipEuropean Soc Med Oncol; Japanese Soc Med Oncolen_US
dc.identifier.issn0923-7534en_US
dc.identifier.urihttp://hdl.handle.net/11727/4935
dc.identifier.volume30en_US
dc.identifier.wos000491295503112en_US
dc.language.isoengen_US
dc.relation.journalANNALS OF ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleENGOT-EN9/LEAP-001: A phase III, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial canceren_US
dc.typeconferenceObjecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Tıp Fakültesi / Faculty of Medicine
Wos İndeksli Yayınlar Koleksiyonu
Wos Kapalı Erişimli Yayınlar